Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib

Dow Jones

May 09, 2025

By Denny Jacob

Corvus Pharmaceuticals shares jumped 29% in premarket trading after new interim data in a study evaluating soquelitinib.

Shares were trading around $4.33. The stock is down 38% on the year.

The clinical-stage biopharmaceutical company said Thursday that new data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis demonstrated a favorable safety and efficacy profile.

Overall, three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints, said Corvus.

The company said it's on track to initiate a Phase 2 trial before the end of the year.

Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

May 09, 2025 08:35 ET (12:35 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2534894514"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534894514\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2534894514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-09 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534894514","market":"nz","top_or_hot":-1,"title":"Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Corvus Pharmaceuticals shares jumped 29% in premarket trading after new interim data in a study evaluating soquelitinib. \n</p>\n<p>\n  Shares were trading around $4.33. The stock is down 38% on the year. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said Thursday that new data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis demonstrated a favorable safety and efficacy profile. \n</p>\n<p>\n  Overall, three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints, said Corvus. \n</p>\n<p>\n  The company said it's on track to initiate a Phase 2 trial before the end of the year. \n</p>\n<p>\n  Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 09, 2025 08:35 ET (12:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-09 20:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Corvus Pharmaceuticals shares jumped 29% in premarket trading after new interim data in a study evaluating soquelitinib. \n</p>\n<p>\n  Shares were trading around $4.33. The stock is down 38% on the year. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said Thursday that new data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis demonstrated a favorable safety and efficacy profile. \n</p>\n<p>\n  Overall, three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints, said Corvus. \n</p>\n<p>\n  The company said it's on track to initiate a Phase 2 trial before the end of the year. \n</p>\n<p>\n  Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 09, 2025 08:35 ET (12:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2534894514","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534894514","pubTimestamp":1746794100,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Corvus Pharmaceuticals shares jumped 29% in premarket trading after new interim data in a study evaluating soquelitinib.Shares were trading around $4.33. The stock is down 38% on the year.The clinical-stage biopharmaceutical company said Thursday that new data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis demonstrated a favorable safety and efficacy profile.Overall, three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints, said Corvus.The company said it's on track to initiate a Phase 2 trial before the end of the year.Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4139":"生物科技","CRVS":"Corvus Pharmaceuticals, Inc."},"translate_title":"Corvus Pharmaceuticals股价因评估索奎替尼的研究数据而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Corvus Pharmaceuticals shares jumped 29% in premarket trading after new interim data in a study evaluating soquelitinib. \n\n\n  Shares were trading around $4.33. The stock is down 38% on the year. \n\n\n  The clinical-stage biopharmaceutical company said Thursday that new data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis demonstrated a favorable safety and efficacy profile. \n\n\n  Overall, three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints, said Corvus. \n\n\n  The company said it's on track to initiate a Phase 2 trial before the end of the year. \n\n\n  Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 09, 2025 08:35 ET (12:35 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}